Advances in the therapy of the myelodysplastic syndromes

  • Peter A. Kouides
  • John M. Bennett
Part of the Cancer Treatment and Research book series (CTAR, volume 99)


The myelodysplastic syndrome (MDS) has been a most challenging disease for hematologists for decades. In terms of diagnosis, it was less than 20 years ago that the French-American-British (FAB) group developed criteria for the diagnosis and the classification of the myelodysplastic syndromes [1]. The FAB classification has provided a common language for hematologists, morphologists, and pathologists in the investigation of this clonal bone marrow disease, since, studies could be compared in part by stratifying patients into the appropriate MDS subgroup. Since its development, the FAB classification has led to countless studies — from kinder, gentler approaches using various vitamins in hopes of inducing differentiation of the MDS clone to ‘brute force’ approaches of high-dose therapy with allogeneic marrow rescue. This chapter will review therapeutic studies published in the past four years; readers interested in details of earlier studies can consult several references [2,3].


Acute Myeloid Leukemia Clin Oncol Myelodysplastic Syndrome Acute Myelogenous Leukemia Stem Cell Factor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C. 1982. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51: 189–199.PubMedGoogle Scholar
  2. 2.
    Kouides PA, Bennett JM. 1995. Myelodysplastic syndromes. In: Abeloff MD, Armitage JO, Lichter AS, Niederhuber JE (eds), Clinical Oncology. Churchill Livingstone: New York, pp 1977–1998.Google Scholar
  3. 3.
    Schumacher HR, Nand S. 1995. Myelodysplastic Syndromes: Approach to Diagnosis and Treatment. Igaku-Shoin: New York, pp 1–239.Google Scholar
  4. 4.
    Raza A, Gezer S, Mundle S, et al. 1995. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood 86:268–276.PubMedGoogle Scholar
  5. 5.
    Raza A, Mundle S, Iftikhar A, et al. 1995. Simultaneous assessment of cell kinetics and programmed cell death in bone marrow biopsies of myelodysplastics reveals extensive apoptosis as the probable basis for ineffective hematopoiesis. Am J Haematol 48:143–154.Google Scholar
  6. 6.
    Raza A, Mundle S, Shetty V, et al. 1996. A paradigm shift in myelodysplastic syndromes. Leukemia 10:1648–1652.PubMedGoogle Scholar
  7. 7.
    Lepelley P, Campergue L, Grardel N, Preudhomme C, Cosson A, Fenaux P. 1996. Is apoptosis a massive process in myelodysplastic syndromes? Br J Haematol 95:368–371.PubMedGoogle Scholar
  8. 8.
    Magill MK, Macfarlane E, McMullin MF. 1997. Intramedullary apoptosis may simply be a correlate of ineffective hematopoiesis. Br J Haematol 97(Suppl 1):17. (abstract)Google Scholar
  9. 9.
    Yoshida Y, Anzai N, Kawabata H. 1995. Apoptosis in myelodysplasia: a paradox or paradigm. Leuk Res 19:887–891.PubMedGoogle Scholar
  10. 10.
    Rajapaksa R, Ginzton N, Rott LS, Greenberg PL. 1996. Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells. Blood 88:4275–4287.PubMedGoogle Scholar
  11. 11.
    Mundle SD, Venugopal P, Cartlidge JD. 1996. Indication of an involvement of interleukin-1 beta converting enzyme-like protease in intramedullary apoptotic cell death in the bone marrow of patients with myelodysplastic syndromes. Blood 88:2640–2647.PubMedGoogle Scholar
  12. 12.
    Raza A, Shetty V, Dar S, Mundle S, Gregory S, Preisler H. 1997. Successful anti-cytokine based approach to treat Myelodysplastic Syndromes. Leuk Res 21(Suppl l):40. (abstract)Google Scholar
  13. 13.
    Nemunaitis J, Rosenfeld C, Getty L, Boegel F, Meyer W, Jennings LW, Zeigler Z, Shadduck R. 1995. Pentoxifylline and ciprofloxacin in patients with myelodysplastic syndrome. A phase II trial. Am J Clin Oncol 18:189–193.PubMedGoogle Scholar
  14. 14.
    Boogaerts MA, Verhoef GE, Demuynck H. 1996. Treatment and prognostic factors in myelodysplastic syndromes (review). Baillieres Clin Haematol 9:161–183.PubMedGoogle Scholar
  15. 15.
    Mufti GJ. 1992. A guide to risk assessment in the primary myelodysplastic syndrome (review with 128 refs). Haematol Oncol Clin North Am 6:587–606.Google Scholar
  16. 16.
    Greenberg P, Cox C, LeBeau MM, et al. 1997. International scoring system for evaluating prognosis in Myelodysplastic Syndromes. Blood 89:2079–2088.PubMedGoogle Scholar
  17. 17.
    McCarley DL. 1993. New uses for old vitamins. The treatment of myelodysplastic disorders. Med Clin North Am 77:919–929.PubMedGoogle Scholar
  18. 18.
    Morosetti R, Koeffler HP. 1996. Differentiation therapy in myelodysplastic syndromes. Semin Haematol 33:236–245.Google Scholar
  19. 19.
    Januszewicz EH, Firkin FC. 1988. Differentiation in acute myeloid leukemia and myelodysplastic disorders. Is differentiation-induction therapy possible? Aust N Z J Med 18:705–711.PubMedGoogle Scholar
  20. 20.
    Clark RE, Jacobs A, Lush CJ, Smith SA. 1987. Effect of 13-cis-retinoic acid on survival of patients with myelodysplastic syndrome. Lancet 1:763–765.PubMedGoogle Scholar
  21. 21.
    Letendre L, Levitt R, Pierre RV, Schroeder G, Krook JA, Mailliard JE, Morton RF, Tschetter LK. 1995. Myelodysplastic syndrome treatment with danazol and cis-retinoic acid. Am J Haematol 48:233–236.Google Scholar
  22. 22.
    Bourantas KL, Tsiara S, Christou L. 1995. Treatment of 34 patients with myelodysplastic syndromes with 13-CIS retinoic acid. Eur J Haematol 55:235–239.PubMedGoogle Scholar
  23. 23.
    Ferrero D, Bruno B, Pregno P, et al. 1996. Combined differentiating therapy for myelodysplastic syndromes: a phase II study. Leuk Res 20:867–876.PubMedGoogle Scholar
  24. 24.
    Kurzrock R, Estey E, Talpaz M. 1993. All-trans retinoic acid: tolerance and biologic effects in myelodysplastic syndrome. J Clin Oncol 11:1489–1495.PubMedGoogle Scholar
  25. 25.
    Ohno R, Naoe T, Hirano M, Kobayashi M, Hirai H, Tubaki K, Oh H. 1993. Treatment of myelodysplastic syndromes with all-trans retinoic acid. Leukemia Study Group of the Ministry of Health and Welfare. Blood 81:1152–1154.PubMedGoogle Scholar
  26. 26.
    Aul C, Runde V, Gattermann N. 1993. All-trans retinoic acid in patients with myelodysplastic syndromes: results of a pilot study. Blood 82:2967–2974.PubMedGoogle Scholar
  27. 27.
    Visani G, Tosi P, Manfroi S, Ottaviani E, Finelli C, Cenacchi A, Bendandi M, Tura S. 1995. All-trans retinoic acid in the treatment of myelodysplastic syndromes. Leuk Lymphoma 19:277–280.PubMedGoogle Scholar
  28. 28.
    Cambier N, Wattel E, Menot ML, Guerci A, Chomienne C, Fenaux P. 1996. All-trans retinoic acid in adult chronic myelomonocytic leukemia: results of a pilot study Leukemia 10:1164–1167.PubMedGoogle Scholar
  29. 29.
    Viniou N, Micjali E, Meletis J, Andreopoulos A, Vaiopoulos G, Stavroyianni N, Loukopoulos D, Yataganas X. 1997. Trisomy 8 in a patient who responded to therapy with all-trans-retinoic acid and developed paroxysmal nocturnal hemoglobinuria. Br J Haematol 97:135–136.PubMedGoogle Scholar
  30. 30.
    Ganser A, Seipelt G, Verbeek W, et al. 1994. Effect of combination therapy with all-trans-retinoic acid and recombinant human granulocyte colony-stimulating factor in patients with myelodysplastic syndromes. Leukemia 8:369–375.PubMedGoogle Scholar
  31. 31.
    Ganser A, Maurer A, Contzen C, et al. 1996. Improved multilineage response of hematopoiesis in patients with myelodysplastic syndromes to a combination therapy with all-transretinoic acid, granulocyte colony-stimulating factor, erythropoietin and alpha-tocopherol. Ann Haematol 72:237–244.Google Scholar
  32. 32.
    Maurer AB, Ganser A, Seipelt G, Ottmann OG, Mentzel U, Geissler GR, Hoelzer D. 1995. Changes in erythroid progenitor cell and accessory cell compartments in patients with myelodysplastic syndromes during treatment with all-trans retinoic acid and haemopoietic growth factors. Br J Haematol 89:449–456.PubMedGoogle Scholar
  33. 33.
    Andreeff M, Stone R, Michaeli J, Young CW, Tong WP, Sogoloff H, Ervin T, Kufe D, Rifkind RA, Marks PA. 1992. Hexamethylene bisacetamide in myelodysplastic syndrome and acute myelogenous leukemia: a phase II clinical trial with a differentiation-inducing agent. Blood 80:2604–2609.PubMedGoogle Scholar
  34. 34.
    Rowinsky EK, Donehower RC, Spivak JL, Burke PJ, Griffin CA, Jones RJ. 1990. Effects of the differentiating agent hexamethylene bisacetamide on normal and myelodysplastic hematopoietic progenitors. J Natl Cancer Inst 82:1926–1931.PubMedGoogle Scholar
  35. 35.
    Petti MC, Latagliata R, Avvisati G, Spiriti MA, Montefusco E, Spadea A, Mandelli F. 1996. Treatment of high-risk myelodysplastic syndromes with lymphoblastoid alpha interferon. Br J Haematol 95:364–367.PubMedGoogle Scholar
  36. 36.
    Motomura S, Fujisawa S, Tsunooka N, Fujimaki K, Mohri H, Okubo T. 1997. Hematologic benefits of 1-hydroxyvitamin D3 in an elderly patient with chronic myelodysplastic syndrome. Am J Haematol 53:143–144.Google Scholar
  37. 37.
    Silverman LR, Holland JF, Weinberg RS, et al. 1993. Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Leukemia 7(Suppl l):21–29.PubMedGoogle Scholar
  38. 38.
    Wijermans PW, Krulder JW, Huijgens PC, Neve P. 1997. Continuous infusion of low-dose 5-Aza-2’-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome. Leukemia 11:1–5.PubMedGoogle Scholar
  39. 39.
    Zagonel V, Lo Re G, Marotta G, Babare R, Sardeo G, Gattei V, De Angelis V, Monfardini S, Pinto A. 1993. 5-Aza-2’-deoxycytidine (Decitabine) induces trilineage response in unfavourable myelodysplastic syndromes. Leukemia 7(Suppl l):30–35.PubMedGoogle Scholar
  40. 40.
    Pinto A, Zagonel V. 1993. 5-Aza-2’-deoxycytidine (Decitabine) and 5-azacytidine in the treatment of acute myeloid leukemias and myelodysplastic syndromes: past, present and future trends (review). Leukemia 7(Suppl l):51–60.PubMedGoogle Scholar
  41. 41.
    List A, Capizzi R, Heaton R, Glinsmann-Gibson B, Brasfield F, Taetle R, Schein P. 1997. Promotion of multilineage hematopoiesis in patients with Myelodysplastic Syndromes: a phase I/II clinical trial with Amifostine. Leuk Res 21(Suppl 1):47. (abstract)Google Scholar
  42. 42.
    Uhr M, Marini GL, Goldhirsch A, Cavalli F. 1997. Tamoxifen as a treatment for the Myelodysplastic Syndromes? A case report (abstract). Leuk Res 21(Suppl 1):43.Google Scholar
  43. 43.
    Vadhan-Raj S. 1997. Recombinant human hemoglobin for patients with anemia. Leukemia Insights Newsletter of the University of Texas M.D. Anderson Cancer Center 2:6.Google Scholar
  44. 44.
    Cheson BD, Jasperse DM, Simon R, Friedman MA. 1986. A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes. J Clin Oncol 4:1857–1864.PubMedGoogle Scholar
  45. 45.
    Kuriya S, Murai K, Miyairi Y, Utsugisawa T, Narigasawa Y, Ito T, Shimosegawa K, Ishida Y. 1996. A combination chemotherapy with low doses of cytarabine and etoposide for high risk myelodysplastic syndromes and their leukemic stage. A pilot study. Cancer 78:422–426.PubMedGoogle Scholar
  46. 46.
    Munshi NC, Tricot GJ. 1997. Single weekly cytosine arabinoside and oral 6-thioguanine in patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia. Ann Haematol 74:111–115.Google Scholar
  47. 47.
    Im T, Yamane T, Mugitani A, Hiyoshi M, Park K, Tatsumi N. 1994. Treatment with cytosine arabinoside and granulocyte colony-stimulating factor in patients with myelodysplastic syndrome and its leukemic phase. Int J Haematol 60:215–223.Google Scholar
  48. 48.
    Gerhartz HH, Zwierzina HH, Walther J, Fenaux P, Hayat M, Jacobs A, Hoffbrand AV, Dardenne M, Solbu G, Suciu S. 1996. Interleukin-3 plus low-dose cytosine arabinoside for advanced myelodysplasia: a pilot study. EORTC Leukemia Group. Cancer Invest 14:299–306.PubMedGoogle Scholar
  49. 49.
    Juneja HS, Jodhani M, Gardner FH, Trevarthen D, Schottstedt M. 1994. Low-dose ARA-C consistently induces hematologic responses in the clinical 5q-syndrome. Am J Haematol 46:338–342.Google Scholar
  50. 50.
    Greenberg BR, Reynolds RD, Charron CB, Squillace KM, Lessin LS, Case DC Jr, Gams RA. 1993. Treatment of myelodysplastic syndromes with daily oral idarubicin. A phase I-II study. Cancer 71:1989–1992.PubMedGoogle Scholar
  51. 51.
    Doll DC, Sun PC, List AF. 1994. Complete hematologic remission with oral etoposide in a patient with chronic myelomonocytic leukemia and profound dyserythropoiesis. Leuk Res 18:381–384.PubMedGoogle Scholar
  52. 52.
    Ogata K, Nomura T. 1993. Application of low-dose etoposide therapy for myelodysplastic syndromes. Leuk Lymphoma 12:35–39.PubMedGoogle Scholar
  53. 53.
    Wattel E, Guerci A, Hecquet B, et al. 1996. A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Groupe Francais des Myelodysplasies and European CMML Group. Blood 88:2480–2487.PubMedGoogle Scholar
  54. 54.
    Omoto E, Deguchi S, Takaba S, et al. 1996. Low-dose melphalan for treatment of high-risk myelodysplastic syndromes. Leukemia 10:609–614.PubMedGoogle Scholar
  55. 55.
    Kouides PA, Bennett JM. 1996. Morphology and classification of the myelodysplastic syndromes and their pathologic variants (review with 133 refs). Semin Haematol 33:95–110.Google Scholar
  56. 56.
    Ganser A, Heil G, Kolbe K, et al. 1993. Aggressive chemotherapy combined with G-CSF and maintenance therapy with interleukin-2 for patients with advanced myelodysplastic syndrome, subacute or secondary acute myeloid leukemia — initial results. Ann Haematol 66:123–125.Google Scholar
  57. 57.
    Economopoulos T, Papageorgiou E, Stathakis N, Constantinidou M, Parharidou A, Kostourou A, Dervenoulas J, Raptis S. 1996. Treatment of high risk myelodysplastic syndromes with idarubicin and cytosine arabinoside supported by granulocyte-macrophage colony-stimulating factor (GM-CSF). Leuk Res 20:385–390.PubMedGoogle Scholar
  58. 58.
    Gassmann W, Schmitz N, Loffler H, De Witte T. 1996. Intensive chemotherapy and bone marrow transplantation for myelodysplastic syndromes. Semin Haematol 33:196–205.Google Scholar
  59. 59.
    Bernstein SH, Brunetto VL, Davey FR, Wurster-Hill D, Mayer RJ, Stone RM, Schiffer CA, Bloomfield CD. 1996. Acute myeloid leukemia-type chemotherapy for newly diagnosed patients without antecedent cytopenias having myelodysplastic syndrome as defined by French-American-British criteria: a Cancer and Leukemia Group B Study. J Clin Oncol 14:2486–2494.PubMedGoogle Scholar
  60. 60.
    Ruutu T, Hanninen A, Jarventie G, et al. 1997. Intensive chemotherapy of poor prognosis Myelodysplastic Syndrome (MDS) and acute myeloid leukemia following MDS with idarubicin and cytarabine. Leuk Res 21:133–138.PubMedGoogle Scholar
  61. 61.
    Krieger OK, Girschikofsky M, Lang F, Oppitz P, Lutz D. 1997. Cladribine (20CDA) is active in ‘high-risk’ chronic myelomonocytic leukemia and secondary or relapsed acute myelo(mono)cytic leukemia. Leuk Res 21(Suppl 1):48.Google Scholar
  62. 62.
    Feldman EJ, Seiter KP, Ahmed T, Baskind P, Arlin ZA. 1996. Homoharringtonine in patients with myelodysplastic syndrome (MDS) and MDS evolving to acute myeloid leukemia. Leukemia 10:40–42.PubMedGoogle Scholar
  63. 63.
    Beran M, Kantarjian H, O’Brien S, et al. 1996. Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 88:2473–2479.PubMedGoogle Scholar
  64. 64.
    Anderson JE, Appelbaum FR, Fisher LD, et al. 1993. Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. Blood 82:677–681.PubMedGoogle Scholar
  65. 65.
    Anderson JE, Appelbaum FR, Schoch G, et al. 1996. Allogeneic marrow transplantation for refractory anemia: a comparison of two preparative regimens and analysis of prognostic factors. Blood 87:51–58.PubMedGoogle Scholar
  66. 66.
    Sutton L, Chastang C, Ribaud P, et al. 1996. Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: a long-term study of 71 patients Societe Francaise de Greffe de Moelle. Blood 88:358–365.PubMedGoogle Scholar
  67. 67.
    Rapoport AP, DiPersio JF, Martin BA, et al. 1995. Patients > or = age 40 years undergoing autologous or allogeneic BMT have regimen-related mortality rates and event-free survivals comparable to patients < age 40 years. Bone Marrow Transplant 15:523–530.PubMedGoogle Scholar
  68. 68.
    Ratanatharathorn V, Karanes C, Uberti J, et al. 1993. Busulfan-based regimens and allogeneic bone marrow transplantation in patients with myelodysplastic syndromes. Blood 81: 2194–2199.PubMedGoogle Scholar
  69. 69.
    O’Donnell MR, Long GD, Parker PM, et al. 1995. Busulfan/cyclophosphamide as conditioning regimen for allogeneic bone marrow transplantation for myelodysplasia. J Clin Oncol 13:2973–2979.PubMedGoogle Scholar
  70. 70.
    Castro-Malspina H, Childs B, Papadopoulos E, Boulad F, Young J, Small T, Kernan N, Collins N, O’Reilly R. 1997. T-cell depleted (SBA-E-) bone marrow transplantation for Myelodysplastic Syndromes. Leuk Res 21(Suppl 1):51. (abstract)Google Scholar
  71. 71.
    Tsuzuki M, Maruyama F, Kojima H, Ezaki K, Hirano M. 1995. Donor buffy coat infusions for a patient with myelodysplastic syndrome who relapsed following allogeneic bone marrow transplantation. Bone Marrow Transplant 16:487–489.PubMedGoogle Scholar
  72. 72.
    Beguin Y, Collignon J, Laurent C, Fillet G. 1996. Spontaneous complete remission and recovery of donor haemopoiesis without GVHD after relapse and apparent marrow graft rejection in poor-prognosis myelodysplastic syndrome. Br J Haematol 94:507–509.PubMedGoogle Scholar
  73. 73.
    Bressoud A, Chapuis B, Roux E, Cabrol C, Jeannet M, Roosnek E, Helg C. 1996. Donor lymphocyte infusion for a patient with relapsing myelodysplastic syndrome after allogeneic bone marrow transplantation. Blood 88:1902–1903. (letter)PubMedGoogle Scholar
  74. 74.
    Schmitz N, Bacigalupo A, Labopin M, et al. 1996. Transplantation of peripheral blood progenitor cells from HLA-identical sibling donors. European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 95:715–723.PubMedGoogle Scholar
  75. 75.
    Anderlini P, Pierce S, Kantarjian H, Estey E. 1996. Acute myeloid leukemia-type chemotherapy for myelodysplasia. J Clin Oncol 14:1404–1405. (letter)PubMedGoogle Scholar
  76. 76.
    Fenaux P, Morel P, Rose C, Lai JL, Jouet JP, Bauters F. 1991. Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy. Br J Haematol 77:497–501.PubMedGoogle Scholar
  77. 77.
    Estey E. 1997. Treatment of myelodysplasia with AML type therapy vs. allogeneic bone marrow transplantation. Leukemia Insights Newsletter of the University of Texas M.D. Anderson Cancer Center 2:7.Google Scholar
  78. 78.
    Anderson JE, Anasetti C, Appelbaum FR, et al. 1996. Unrelated donor marrow transplantation for myelodysplasia (MDS) and MDS-related acute myeloid leukaemia. Br J Haematol 93:59–67.PubMedGoogle Scholar
  79. 79.
    Demuynck H, Verhoef GE, Zachee P, Emonds MP, van der Schueren E, Van den Berghe H, Vandenberghe P, Casteels-Van Daele M, Boogaerts MA. 1996. Treatment of patients with myelodysplastic syndromes with allogeneic bone marrow transplantation from genotypically HLA-identical sibling and alternative donors. Bone Marrow Transplant 17:745–751.PubMedGoogle Scholar
  80. 80.
    Sahebi F, Copelan E, Crilley P, Bolwell B, Avalos B, Klein J, Territo M, Gajewski J. 1996. Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen. Bone Marrow Transplantation 17:685–689.PubMedGoogle Scholar
  81. 81.
    Laporte JP, Isnard F, Lesage S, Fenaux P, Douay L, Lopez M, Stachowiak J, Najman A, Gorin NC. 1993. Autologous bone marrow transplantation with marrow purged by mafosfamide in seven patients with myelodysplastic syndromes in transformation (AML-MDS): a pilot study. Leukemia 7:2030–2033.PubMedGoogle Scholar
  82. 82.
    Demuynck H, Delforge M, Verhoef GE, Zachee P, Vandenberghe P, Van den Berghe H, Boogaerts MA. 1996. Feasibility of peripheral blood progenitor cell harvest and transplantation in patients with poor-risk myelodysplastic syndromes. Br J Haematol 92:351–359.PubMedGoogle Scholar
  83. 83.
    Delforge M, Demuynck H, Vandenberghe P, Verhoef G, Zachee P, van Duppen V, Marijnen P, Van den Berghe H, Boogaerts MA. 1995. Polyclonal primitive hematopoietic progenitors can be detected in mobilized peripheral blood from patients with high-risk myelodysplastic syndromes. Blood 86:3660–3667.PubMedGoogle Scholar
  84. 84.
    Ganser A, Hoelzer D. 1996. Clinical use of hematopoietic growth factors in the myelodysplastic syndromes (review with 95 refs). Semin Haematol 33:186–195.Google Scholar
  85. 85.
    Rose C, Wattel E, Bastion Y, Berger E, Bauters F, Coiffier B, Fenaux P. 1994. Treatment with very low-dose GM-CSF in myelodysplastic syndromes with neutropenia. A report on 28 cases. Leukemia 8:1458–1462.PubMedGoogle Scholar
  86. 86.
    Schuster MW, Thompson JA, Larson R, Allen SL, O’Laughlin R, Israel R, Fefer A. 1990. Randomized trial of subcutaneous granulocyte-macrophage colony stimulating factor versus observation in patients with Myelodysplastic Syndrome or Aplastic Anemia. Proc Am Soc Clin Oncol 9:205. (abstract)Google Scholar
  87. 87.
    Greenberg P, Taylor K, Koeffler P, et al. 1993. Phase III randomized multicenter trial of G-CSF vs. observation for myelodysplastic syndromes. Blood 82(Suppl 1):196. (abstract)Google Scholar
  88. 88.
    Chiba S, Inamori K, Mitani K, Hirai H, Yazaki Y. 1994. Marked and reproducible increase in trilineage blood cell counts by administration of granulocyte colony-stimulating factor in a patient with refractory anaemia with excess blasts in transformation. Br J Haematol 86:665–667.PubMedGoogle Scholar
  89. 89.
    Perugini O, Montanari G, Nalli G. 1995. Trilineage response to granulocyte colony-stimulating factor administration in a patient with myelodysplastic syndrome. Haemato logica 80:234–237.Google Scholar
  90. 90.
    Takahashi M, Yoshida Y, Kaku K, Masaoka T, Moriyama Y, Nakanishi S, Kaneko T, Shibata A, Miwa S. 1993. Phase II study of recombinant human granulocyte-macrophage colony-stimulating factor in myelodysplastic syndrome and aplastic anemia. Acta Haematol 89:189–194.PubMedGoogle Scholar
  91. 91.
    Hellstrom-Lindberg E. 1995. Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. Br J Haematol 89:67–71.PubMedGoogle Scholar
  92. 92.
    Hellstrom-Lindberg E, Birgegard G, Carlsson M, et al. 1993. A combination of granulocyte colony-stimulating factor and erythropoietin may synergistically improve the anaemia in patients with myelodysplastic syndromes. Leuk Lymphoma 11:221–228.PubMedGoogle Scholar
  93. 93.
    Negrin RS, Stein R, Vardiman J, Doherty K, Cornwell J, Krantz S, Greenberg PL. 1993. Treatment of the anemia of myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor in combination with erythropoietin. Blood 82:737–743.PubMedGoogle Scholar
  94. 94.
    Takahashi M, Aoki A, Mito M, Nikkuni K, Ohtsuka T, Saitoh H, Moriyama Y, Shibata A. 1993. Combination therapy with rhGM-CSF and rhEpo for two patients with refractory anemia and aplastic anemia. Haematol Pathol 7:153–158.Google Scholar
  95. 95.
    Hansen PB, Johnsen HE, Hippe E, Hellstrom-Lindberg E, Ralfkiaer E. 1993. Recombinant human granulocyte-macrophage colony-stimulating factor plus recombinant human erythropoietin may improve anemia in selected patients with myelodysplastic syndromes. Am J Haematol 44:229–236.Google Scholar
  96. 96.
    Bernell P, Stenke L, Wallvik J, Hippe E, Hast R. 1996. A sequential erythropoietin and GM-CSF schedule offers clinical benefits in the treatment of anaemia in myelodysplastic syndromes. Leuk Res 20:693–699.PubMedGoogle Scholar
  97. 97.
    Stenke L, Wallvik J, Celsing F, Hast R. 1993. Prediction of response to treatment with human recombinant erythropoietin in myelodysplastic syndromes. Leukemia 7:1324–1327.PubMedGoogle Scholar
  98. 98.
    Di Raimondo F, Longo G, Cacciola E Jr, Milone G, Palumbo GA, Cacciola RR, Alessi M, Giustolisi R. 1996. A good response rate to recombinant erythropoietin alone may be expected in selected myelodysplastic patients. A preliminary clinical study. Eur J Haematol 56:7–11.PubMedGoogle Scholar
  99. 99.
    Rose EH, Abels RI, Nelson RA, McCullough DM, Lessin L. 1995. The use of r-HuEpo in the treatment of anaemia related to myelodysplasia (MDS). Br J Haematol 89:831–837.PubMedGoogle Scholar
  100. 100.
    Razzano M, Caslini C, Cortelazzo S, Battistel V, Rambaldi A, Barbui T. 1993. Clinical and biological effects of erythropoietin treatment of myelodysplastic syndrome. Leuk Lymphoma 10:127–134.PubMedGoogle Scholar
  101. 101.
    Ghio R, Balleari E, Ballestrero A, Gatti AM, Mareni C, Massa G, Patrone F, Sessarego M, Timitilli S. 1993. Subcutaneous recombinant human erythropoietin for the treatment of anemia in myelodysplastic syndromes. Acta Haematol 90:58–64.PubMedGoogle Scholar
  102. 102.
    Cazzola M, Ponchio L, Pedrotti C, Farina G, Cerani P, Lucotti C, Novella A, Rovati A, Bergamaschi G, Beguin Y. 1996. Prediction of response to recombinant human erythropoietin (rHuEpo) in anemia of malignancy. Haematologica 81:434–441.PubMedGoogle Scholar
  103. 103.
    Musto P, Scalzulli PR, Carotenuto M. 1995. Recombinant erythropoietin for myelodysplastic syndromes. Br J Haematol 91:256–258. (letter)PubMedGoogle Scholar
  104. 104.
    Bowen DT, Culligan D, Beguin Y, Kendall R, Willis N. 1994. Estimation of effective and total erythropoiesis in myelodysplasia using serum transferrin receptor and erythropoietin concentrations, with automated reticulocyte parameters. Leukemia 8:151–155.PubMedGoogle Scholar
  105. 105.
    Musto P, Modoni S, Alicino G, et al. 1994. Modifications of erythropoiesis in myelodysplastic syndromes treated with recombinant erythropoietin as evaluated by soluble transferrin receptor, high fluorescence reticulocytes and hypochromic erythrocytes. Haematologica 79: 493–499.PubMedGoogle Scholar
  106. 106.
    Hoefsloot LH, Vanamelsvoort MP, Breeders LCAM, Vanderplas DC, Vanlom K, Hoogerbrugge H, Touw IP, Lowenberg B. 1997. Erythropoietin-induced activation of STAT5 is impaired in the Myelodysplastic Syndrome. Blood 89:1690–1700.PubMedGoogle Scholar
  107. 107.
    Ganser A, Seipelt G, Lindemann A, et al. 1990. Effects of recombinant human interleukin-3 in patients with myelodysplastic syndromes. Blood 76:455–462.PubMedGoogle Scholar
  108. 108.
    Kurzrock R, Talpaz M, Estrov Z, Rosenblum MG, Gutterman JU. 1991. Phase I study of recombinant human interleukin-3 in patients with bone marrow failure. J Clin Oncol 9:1241–1250.PubMedGoogle Scholar
  109. 109.
    Bowen D, Yancik S, Bennett L, Culligan D, Resser K. 1993. Serum stem cell factor concentration in patients with myelodysplastic syndromes. Br J Haematol 85:63–66.PubMedGoogle Scholar
  110. 110.
    Zwierzina H, Bammer T, Rollingerholzinger I, Herold M, Fenaux P, Nussler V, Hoeflehner E, Geissler D. 1997. In vitro stimulation of erythropoiesis by stem cell factor alone in Myelodysplastic Syndrome patients with elevated endogenous erythropoietin serum levels. Clin Cancer Res 2:1031–1038.Google Scholar
  111. 111.
    Masters GS, Baines P, Tang C, Bowen D, Burnett AK. 1995. Responsiveness to stem cell factor (SCF) of peripheral blood colony-forming cells from patients with myelodysplastic syndromes (MDS). Leuk Res 19:561–566.PubMedGoogle Scholar
  112. 112.
    Wu HK, Chiba S, Hirai H, Takaku F, Yazaki Y. 1994. Effect of stem cell factor (c-kit ligand) on clonogenic leukemic precursor cells: synergy with other hematopoietic growth factors. Am J Haematol 47:328–330.Google Scholar
  113. 113.
    Gordon MS, Nemunaitis J, Hoffman R, Paquette RL, Rosenfeld C, Manfreda S, Isaacs R, Nimer SD. 1995. A phase I trial of recombinant human interleukin-6 in patients with myelodysplastic syndromes and thrombocytopenia. Blood 85:3066–3076.PubMedGoogle Scholar
  114. 114.
    Kunishima S, Tahara T, Kato T, Kobayashi S, Saito H, Naoe T. 1996. Serum thrombopoietin and plasma glycocalicin concentrations as useful diagnostic markers in thrombocytopenic disorders. Eur J Haematol 57:68–71.PubMedGoogle Scholar
  115. 115.
    Chabannon C, Molina L, Pegourie-Bandelier B, Bost M, Leger J, Hollard D. 1994. A review of 76 patients with myelodysplastic syndromes treated with danazol. Cancer 73:3073–3080.PubMedGoogle Scholar
  116. 116.
    Wattel E, Cambier N, Caulier MT, Sautiere D, Bauters F, Fenaux P. 1994. Androgen therapy in myelodysplastic syndromes with thrombocytopenia: a report on 20 cases. Br J Haematol 87:205–208.PubMedGoogle Scholar
  117. 117.
    Hebbar M, Kaplan C, Caulier MT, Wattel E, Morel P, Wetterwald M, Bauters F, Fenaux P. 1996. Low incidence of specific anti-platelet antibodies detected by the MAIPA assay in the serum of thrombocytopenic MDS patients and lack of correlation between platelet autoantibodies, platelet lifespan and response to danazol therapy. Br J Haematol 94:112–115.PubMedGoogle Scholar
  118. 118.
    Stadtmauer EA, Cassileth PA, Edelstein M, Abrahm J, Schreiber AD, Nowell PC, Cines DB. 1991. Danazol treatment of myelodysplastic syndromes. Br J Haematol 77:502–508.PubMedGoogle Scholar
  119. 119.
    Jensen PD, Heickendorff L, Pedersen B, Bendix-Hansen K, Jensen FT, Christensen T, Boesen AM, Ellegaard J. 1996. The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload. Br J Haematol 94:288–299.PubMedGoogle Scholar
  120. 120.
    Holcombe RF. 1993. Mini-dose interferon alpha-2a in the treatment of myelodysplasia. Leukemia 7:192–195.PubMedGoogle Scholar
  121. 121.
    Stone RM, Spriggs DR, Arthur KA, Mayer RJ, Griffin J, Kufe DW. 1993. Recombinant human gamma interferon administered by continuous intravenous infusion in acute myelogenous leukemia and myelodysplastic syndromes. Am J Clin Oncol 16:159–163.PubMedGoogle Scholar
  122. 122.
    Ogata K, Yokose N, Nomura T. 1995. Interleukin-2 therapy for myelodysplastic syndrome: does it work? Leuk Lymphoma 17:411–415.PubMedGoogle Scholar
  123. 123.
    Rosenfeld CS, Zeigler ZR, Shadduck RK, Nilsson B. 1997. Phase II study of roquinimex in Myelodysplastic Syndrome. Am J Clin Oncol 20:189–192.PubMedGoogle Scholar
  124. 124.
    Biesma DH, Vandentweel JG, Verdonck LF. 1997. Immunosuppressive therapy for hypoplastic Myelodysplastic Syndrome. Cancer 79:1548–1551.PubMedGoogle Scholar
  125. 125.
    Ogata K, Yokose N, Ito T, An E, Tamura H, Dan K, Hamaguchi H, Sakamaki H, Onozawa Y, Nomura T. 1994. Assessment of therapeutic potential of interleukin 2 for myelodysplastic syndromes. Br J Haematol 86:562–567.PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers, Boston 1999

Authors and Affiliations

  • Peter A. Kouides
  • John M. Bennett

There are no affiliations available

Personalised recommendations